亚洲日韩欧美综合-亚洲日韩欧美一区二区在线-亚洲日韩欧美视频-亚洲日韩精品欧美一区二区-国产欧美日韩综合

會員登錄|免費注冊|忘記密碼|管理入口 返回主站||保存桌面|手機瀏覽|聯(lián)系方式|購物車
企業(yè)會員第1年

北京萊瑞森醫(yī)藥科技有限公司  

醫(yī)藥原料藥和中間體,替莫唑胺、磷酸氟達拉濱、阿德福韋酯、阿米舒必利、鹽酸吉西他濱、培美曲塞二鈉、伏立康唑、法羅培南鈉、阿米酸、阿加曲班中間體.....

搜索
新聞中心
  • 暫無新聞
產(chǎn)品分類
聯(lián)系方式
  • 聯(lián)系人:劉巧麗
  • 電話:86-010-80771378-8017
  • 郵件:lunarsunliu@hotmail.com
  • 傳真:010-80771338
  • QQ:873162955
站內(nèi)搜索
 
榮譽資質(zhì)
  • 暫未上傳
友情鏈接
  • 暫無鏈接
首頁 > 供應(yīng)產(chǎn)品 > 培美曲塞二鈉,CAS登錄號:150399-23-8
培美曲塞二鈉,CAS登錄號:150399-23-8
單價 面議對比
詢價 暫無
發(fā)貨 北京付款后3天內(nèi)
品牌 萊瑞森醫(yī)藥
型號 150399-23-8
規(guī)格 醫(yī)藥級
過期 長期有效
更新 2012-03-26 21:07
 
詳細信息

產(chǎn)品名稱:培美曲塞二鈉
中文別名: N-[4-[2-(2-氨基-4,7-二氫-4-氧代-1H-吡咯[2,3-d]嘧啶-5-基)乙基]苯甲酰]-L-谷氨酸二鈉
CAS登錄號:150399-23-8
英文名稱:Pemetrexed disodium
分子式:C20H19N5NA2O6
分子量:471.37
©2025 北京萊瑞森醫(yī)藥科技有限公司 版權(quán)所有   技術(shù)支持:化工網(wǎng)   訪問量:11192  
 
主站蜘蛛池模板: | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |